Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?

Taking stock of the drug industry, from the lab to the medicine chest

August 14, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Pat Greenhouse/The Boston Globe STAT+ | Eli Lilly's billions: Can the world's most valuable pharma company keep inventing drugs at this pace? Inventing a mega-blockbuster — in this case novel drugs that treat obesity and diabetes — brings its own set of challenges. By Matthew Herper Opinion: Better safety studies could restore America's confidence in vaccines I study vaccines for a living. A Covid-19 shot worsened my tinnitus. The U.S. needs stronger research on vaccine safety. By Gregory A. Poland STAT+ | Illumina lays out plan to boost growth by helping scientists interpret sequencing data Illumina CEO Jacob Thaysen made clear the sequencing giant is returning to its traditional role of creating instruments for researchers. By Jonathan Wosen Grail STAT+ | Grail announces layoffs as it looks to push forward blood-based cancer detection test The layoffs were announced the same day as its Q2 financial report, its first since it was divested by DNA sequencing juggernaut Illumina in June. By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser